How the product works:
Imatinib is a selective tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. It blocks abnormal signaling pathways in cancer cells, inhibiting proliferation and inducing apoptosis while sparing normal cells.
Who it is recommended for:
Clinical studies and evidence:
Imatinib revolutionized cancer treatment as the first successful targeted therapy. Its efficacy and safety have been demonstrated in large-scale international clinical trials, including the IRIS study, and it is included in global oncology treatment guidelines.
The drug is used to inhibit tumor cell growth by blocking tyrosine kinase activity.
The medication is taken orally with food and a full glass of water. Dosage and treatment duration are determined individually by a healthcare professional based on the specific diagnosis and therapeutic response.
Contraindications:
Side effects:
